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per  BclI allele, 95% CI: 1.02–1.23, p = 0.013) in a logistic re-
gression model adjusted for gestational age, mechanical 
ventilation, and small for gestational age status. A similar rel-
ative risk was seen in the children (89.4%) who received an-
tenatal betamethasone treatment (OR 1.16, 95% CI: 1.05–
1.27, p = 0.003), whereas no such effect was detectable in 
infants without antenatal steroids.  N363S and  R23K did not 
show any stable association with neonatal outcome param-
eters.  Conclusion: Except for a slightly higher risk of BPD in 
carriers of the  GR  BclI variant, the  GR gene polymorphisms 
 BclI, N363S, and  R23K did not affect neonatal outcome pa-
rameters in this large multicenter cohort of VLBW preterm 
infants.  © 2016 S. Karger AG, Basel 
 Introduction 
 In 1969 Graham Liggins demonstrated accelerated fe-
tal lung maturation after antenatal corticosteroid admin-
istration in premature lambs  [1] and shortly thereafter in 
humans  [2] . Antenatal corticosteroid treatment signifi-
cantly reduces the risk of respiratory distress syndrome 
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 Abstract 
 Background: Induction of lung maturation by prenatal ste-
roid treatment has become the standard of care for pregnant 
women at risk for preterm birth. In addition to the beneficial 
effects on lung maturation, prenatal steroids have been 
shown to reduce the incidence of neonatal death, necrotiz-
ing enterocolitis, sepsis, and intraventricular hemorrhage. 
However, little is known about the role of interindividual dif-
ferences in corticoid sensitivity arising from polymorphisms 
in the glucocorticoid receptor  (GR) gene.  Objectives: To as-
sess the impact of  GR polymorphisms  N363S (rs56149945), 
 R23K (rs6190), and  BclI (rs41423247) on neonatal outcome. 
 Methods: The  GR polymorphisms  N363S, R23K, and  BclI were 
examined in 10,490 very-low-birth-weight (VLBW) preterm 
infants from 49 German tertiary level neonatal units (German 
Neonatal Network, GNN) with respect to neonatal outcome. 
 Results: Infants carrying the  BclI genotype were at higher 
risk to develop bronchopulmonary dysplasia (BPD) (OR 1.12 
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(RDS) and has become a standard of care for all pregnant 
women at risk of preterm birth less than 34 weeks of ges-
tation. In addition to the beneficial effect on lung matura-
tion, prenatal steroid treatment has been shown to reduce 
the incidence of neonatal death, necrotizing enterocolitis 
(NEC), sepsis, and intraventricular hemorrhage (IVH) 
 [3] .
 We hypothesized that genetically determined differ-
ences in glucocorticoid sensitivity may modify the re-
sponse to corticosteroids and thus represent a factor in-
fluencing the clinical outcome of preterm infants. Dif-
ferences in the individual glucocorticoid sensitivity are 
mediated by glucocorticoid receptor ( GR ) gene polymor-
phisms, among which both variants with increased 
 (N363S ,  BclI) and decreased  (R23K) receptor sensitivity 
exist  [4] . These variants may not only modify the re-
sponse to exogenous synthetic steroids such as betameth-
asone, but could also modify the effects of endogenous 
corticosteroids during pre- and perinatal life.
 So far,  GR gene polymorphisms have been analyzed in 
mostly small cohorts of preterm infants with conflicting 
results  [5–10] . However, considering the comparatively 
low allele frequencies for  N363S and  R23K and the need 
to stratify for antenatal corticosteroid treatment, verifica-
tion of this compelling hypothesis may require substan-
tially larger study samples. In this study, we aimed to de-
termine the effects of  GR gene polymorphisms  BclI , 
 N363S , and  R23K on neonatal outcome parameters in a 
large multicenter cohort of more than 10,000 very-low-
birth-weight (VLBW; birth weight <1,500 g) preterm in-
fants.
 Patients and Methods 
 The study cohort comprised a total of 10,490 VLBW infants. 
10,413 infants were prospectively enrolled in a multicenter study 
of the German Neonatal Network (GNN; 48 German tertiary level 
neonatal units) between 2003 and 2013; 77 infants were initially 
recruited as part of a single-center study at the Department of Neo-
natology, University of Bonn, which became affiliated with the 
GNN network later on. Since inclusion of multiple siblings with 
identical or similar genetic backgrounds as well as shared intra-
uterine environment increases the risk of spurious genotype-phe-
notype associations, only one sibling of each group of multiples 
was selected on a random basis to be included into the study sam-
ples. Personal data were pseudonymized prior to genotyping and 
statistical analysis. The study was approved by the ethics commit-
tees of all participating hospitals. Written informed consent was 
obtained from all parents.
 DNA for genotyping was extracted from buccal swabs or um-
bilical cord tissue using standard protocols (QIAamp 96 DNA Kit 
and Gentra Puregene Tissue Kit; Qiagen, Hilden, Germany). Ge-
notypes for the  GR gene variants  N363S (rs56149945),  R23K 
(rs6190), and  BclI (rs41423247) were analyzed automatically on an 
Applied Biosystems 7900HT platform (GNN, Lübeck, Germany) 
or by restriction fragment length polymorphism (initial Bonn co-
hort; for primers and reaction conditions see Schreiner  [11] ). Out 
of a total of 10,490 samples, genotyping was successful in 10,201 
 (BclI) , 9,851  (R23K) , and 10,322  (N363S) samples. Because of the 
small number of samples homozygous for 363S or 23K alleles, 
those heterozygous and homozygous for the mutant allele were 
grouped for statistical analyses. In order to exclude potential con-
founding effects of compound heterozygosity or double mutants, 
all statistic tests were repeated comparing samples carrying only 
one  GR variant (= pure carrier) against those carrying only wild-
type alleles at all three polymorphic loci (= pure noncarrier).
 Detailed information on clinical definitions is given in previ-
ous publications of the GNN group  [12, 13] . Small for gestation-
al age (SGA) was defined as birth weight below the 10th percentile 
according to Voigt et al.  [14] . Ethnicity was assessed by the moth-
er’s report on her racial background. Bronchopulmonary dyspla-
sia (BPD) was classified according to Walsh et al.  [15] . Supple-
mental oxygen <30% with desaturation <90% during an oxygen 
reduction test, supplemental oxygen >30%, and/or requirement 
of CPAP/mechanical ventilation were classified as ‘BPD’ at 36 
weeks’ gestational age. Any kind of mechanical ventilation after 
endotracheal intubation during the hospital stay was classified as 
mechanical ventilation, whereas CPAP was documented as a sep-
arate variable. Any use of surfactant was expressed by the variable 
surfactant therapy. IVH was defined as any bleeding into the ger-
minal matrix or ventricles. The lowest blood pressure on the first 
day of life was defined as the lowest documented mean arterial 
blood pressure during the first day of life. We separately assessed 
clinical sepsis, defined as any suspected sepsis with obvious clin-
ical symptoms  [16] , and blood-culture confirmed sepsis. Blood-
culture-confirmed sepsis was further separated into early-onset 
sepsis if the onset was within 72 h of life and late-onset sepsis. 
Treatment of retinopathy of prematurity (ROP) with laser coagu-
lation or cryocoagulation was expressed as surgery for ROP. Any 
surgical treatment of NEC was expressed by the variable surgery 
for NEC. Indications for surgery of ROP, PDA, and NEC were 
based on the local treatment standard of each participating cen-
ter.
 Statistical analyses were performed using the SPSS software 
package, version 22 (SPSS Inc., Chicago, Ill., USA). Differences 
between genotype groups were analyzed by a χ 2 test, Fisher’s exact 
test, or ANOVA. Logistic regression analysis was used to assess the 
influence of  GR genotypes and other factors on binary variables 
such as BPD or IVH. Effect sizes for other variables were analyzed 
by linear regression analyses. Generally, statistical significance was 
assumed for p values <0.05.
 Results 
 Clinical data stratified for  GR polymorphisms  BclI , 
 N363S , and  R23K are presented in  tables 1–3 . Genotypes 
were in Hardy-Weinberg equilibrium and allele frequen-
cies were comparable with those reported previously 
from other Western European populations  [4, 11] .
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 BclI 
 Carriers of the  BclI variant were more likely to suffer 
from BPD (16.4 vs. 14.6%, p = 0.015), whereas birth pa-
rameters and frequencies of CPAP and/or mechanical 
ventilation requirement did not differ between  BclI geno-
type groups ( table 1 ). This genotype effect was reproduc-
ible in different subgroups of infants with a high BPD risk 
( table 4 ). Binary logistic regression analysis revealed a sig-
nificant contribution of mechanical ventilation (OR 6.50, 
95% CI: 5.43–7.85), gestational age (OR 0.74 per week, 
95% CI: 0.72–0.76), SGA status (OR 2.82, 95% CI: 2.41–
3.30), and  BclI genotype (OR 1.12 per  BclI allele, 95% CI: 
1.02–1.23, p = 0.013) to the individual risk of BPD. A sim-
ilar relative risk was seen in the subcohort of infants with 
antenatal steroid treatment (n = 9,065, OR 1.16, 95% CI: 
1.05–1.27, p = 0.003). In contrast, no such effect was de-
tectable in the subgroup without antenatal steroid expo-
sure (n = 1,094, OR 0.86, 95% CI: 0.64–1.15). A subcohort 
analysis of 8,359 individuals being either  BclI pure carri-
ers (i.e. wild-type at positions p.363 and p.23) or pure 
noncarriers (wild-type at all three loci), however, slightly 
attenuated the observed association between  BclI and 
BPD (CC 15.1% vs. CG 16.1% vs. GG 17.0%, p > 0.2; OR 
1.09, 95% CI: 0.99–1.21, p = 0.08; infants with antenatal 
steroids: OR 1.12, 95% CI: 1.01–1.24, p = 0.030). Inclu-
sion of ethnicity into analysis also did not further strength-
en the observed association between BPD and  BclI geno-
type (Caucasians, total n = 8,465: 16.4 vs. 14.4%, p = 0.051; 
OR 1.14, 95% CI: 1.02–1.27, p = 0.025; Middle East and 
Turkey, total n = 895: 16.5 vs. 15.2%, p > 0.2; OR 1.14, 95% 
CI: 0.78–1.66, p > 0.2).
 Nominally significant associations were also detected 
for  BclI and the individual risk to develop PVL, ROP re-
quiring surgical intervention, and late-onset sepsis, respec-
 Table 1.  Clinical data with respect to the BclI genotype
Genotype BclI (n = 10,201)  p value
–/– (4,427) +/– (4,600) +/+ (1,174) – /–, +/–, +/+ –/– vs. carrier
Gestational age, weeks 28.28 ± 2.74 28.32 ± 2.70 28.29 ± 2.71 0.760 0.506
Birth weight, g 1,058 ± 302 1,063 ± 305 1,067 ± 294 0.578 0.299
Gender, males 50.0 51.4 52.1 0.289 0.131
Singletons 66.6 66.5 65.4 0.731 0.733
SGA <10th percentile 17.9 19.1 16.6 0.091 0.356
Apgar 5 min 7.72 ± 1.50 7.78 ± 1.82 7.81 ± 1.47 0.139 0.077
Apgar 10 min 8.59 ± 1.10 8.60 ± 1.10 8.63 ± 1.07 0.616 0.380
PDA /drug intervention 22.5 22.4 23.7 0.629 0.893
Lowest RR 1st dol, mm Hg 27.90 ± 6.62 28.08 ± 6.36 27.94 ± 6.88 0.358 0.204
Inotropes 17.9 19.5 19.1 0.144 0.052
Antenatal steroids 89.2 89.7 87.4 0.076 0.916
Surfactant 56.4 56.2 57.5 0.737 0.986
CPAP 83.1 83.7 83.4 0.739 0.460
Mechanical ventilation 47.0 47.6 48.8 0.561 0.405
BPD 14.6 16.3 17.0 0.045 0.015
Dexamethasone (postnatal) 4.0 4.7 5.2 0.127 0.056
Steroids (postnatal) 11.2 11.9 13.7 0.064 0.112
IVH 16.7 17.1 18.3 0.402 0.370
PVL 2.9 3.8 3.6 0.073 0.023
PDA surgery 4.7 4.8 4.2 0.714 1.000
NEC surgery 2.5 2.6 3.1 0.506 0.464
ROP surgery 2.7 3.3 3.4 0.142 0.048
Sepsis (clinical) 31.8 31.5 32.7 0.716 0.877
Sepsis (culture-proven) 13.6 12.5 14.2 0.176 0.257
Sepsis (early-onset) 1.4 1.2 2.0 0.152 0.935
Sepsis (late-onset) 9.8 9.1 11.5 0.041 0.681
Death 3.0 3.5 2.7 0.234 0.285
 Data are expressed as means ± SD or %. Italics represent significant values.
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tively. Whereas  BclI and PVL also exhibited a significant 
relation in binary regression analysis including gestational 
age and antenatal steroids as covariables (OR 1.18, 95% CI: 
1.01–1.39, p = 0.038), outcome variables ROP surgery and 
late-onset sepsis did not reveal significant associations in 
regression analyses. Similarly, pure carrier analyses did not 
show significant associations between any of the variables 
PVL, ROP, and sepsis to the  BclI genotype.
 Table 2.  Clinical data with respect to the N363S genotype
Genotype N363S (n = 10,322)  p value
–/– (9,593) +/– or +/+
(718 + 11)
– /– vs. 
carrier
Gestational age, weeks 28.30 ± 2.73 28.22 ± 2.55 0.278
Birth weight, g 1,061 ± 303 1,056 ± 293 0.568
Gender, males 50.9 50.8 0.956
Singletons 66.4 64.8 0.371
SGA <10th percentile 18.4 16.6 0.224
Apgar 5 min 7.76 ± 1.66 7.69 ± 1.48 0.176
Apgar 10 min 8.60 ± 1.10 8.59 ± 1.07 0.915
PDA/drug intervention 22.7 22.8 0.931
Lowest RR 1st dol, mm Hg 28.03 ± 6.55 27.26 ± 6.31 0.008
Inotropes 18.7 21.0 0.132
Antenatal steroids 89.4 89.1 0.753
Surfactant 56.5 57.8 0.489
CPAP 83.3 83.7 0.817
Mechanical ventilation 47.3 51.4 0.032
BPD 15.7 16.4 0.608
Dexamethasone (postnatal) 4.4 4.8 0.621
Steroids (postnatal) 11.8 13.2 0.258
IVH 17.0 18.0 0.493
PVL 3.3 4.4 0.119
PDA surgery 4.7 4.2 0.528
NEC surgery 2.7 2.4 0.590
ROP surgery 3.0 2.8 0.736
Sepsis (clinical) 31.8 32.4 0.743
Sepsis (culture-proven) 13.1 13.1 0.969
Sepsis (early-onset) 1.4 2.0 0.192
Sepsis (late-onset) 9.7 9.3 0.757
Death 3.3 3.0 0.749
 Data are expressed as means ± SD or %. Italics represent sig-
nificant values.
 Table 3.  Clinical data with respect to the R23K genotype
Genotype R23K (n = 9,851) p  value
–/– (9,353) +/– or +/+
(493 + 5)
– /– vs.
carrier
Gestational age, weeks 28.27 ± 2.70 28.48 ± 2.74 0.105
Birth weight, g 1,058 ± 303 1,080 ± 294 0.142
Gender, males 51.1 49.4 0.449
Singletons 66.2 63.2 0.159
SGA <10th percentile 18.3 16.1 0.210
Apgar 5 min 7.74 ± 1.50 7.96 ± 3.49 0.424
Apgar 10 min 8.59 ± 1.10 8.63 ± 1.08 0.322
PDA/drug intervention 23.0 21.1 0.326
Lowest RR 1st dol, mm Hg 27.97 ± 6.54 28.35 ± 6.66 0.358
Inotropes 19.2 17.8 0.439
Antenatal steroids 89.5 87.7 0.196
Surfactant 57.0 53.5 0.131
CPAP 83.3 85.1 0.316
Mechanical ventilation 47.8 46.2 0.485
BPD 15.9 13.6 0.165
Dexamethasone (postnatal) 4.6 3.5 0.309
Steroids (postnatal) 12.0 10.3 0.256
IVH 17.1 16.4 0.695
PVL 3.4 4.1 0.461
PDA surgery 4.7 4.7 0.980
NEC surgery 2.7 2.9 0.839
ROP surgery 3.1 2.7 0.601
Sepsis (clinical) 31.8 31.9 0.997
Sepsis (culture-proven) 13.1 15.3 0.155
Sepsis (early-onset) 1.4 2.2 0.104
Sepsis (late-onset) 9.7 10.6 0.517
Death 3.3 4.5 0.154
 Data are expressed as means ± SD or %.
 Table 4. BPD and BclI genotypes in BPD high-risk subgroups
High-risk subgroup Infants with BPD according to BclI genotype  p value
–/– +/– +/+ –/– , +/–, +/+ –/– vs.
carrier
SGA (n = 1,858) 19.4 (153/787) 23.5 (206/877) 24.7 (48/65) 0.082 0.028
Pneumothorax (n = 517) 25.5 (51/200) 32.5 (82/252) 36.9 (24/65) 0.127 0.056
Treatment with surfactant (n = 5,705) 22.2 (549/2,475) 25.4 (653/2,566) 25.3 (168/664) 0.018 0.005
Data are expressed as % (n/n). Italics represent significant values.
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 N363S 
 Infants carrying the  N363S variant had lower blood 
pressure at the first day of life and higher rates of me-
chanical ventilation ( table  2 ). The genotype effect on 
blood pressure remained significant after adjustment 
for gestational age (β = –0.023, p = 0.024). Analysis of 
only the children born to Caucasian mothers (n = 8,761) 
revealed similar effect sizes (group comparison 28.10 ± 
6.51 vs. 27.35 ± 6.35, p = 0.012; regression β = –0.021,
p = 0.052) compared to the entire cohort. On the other 
hand, in children of Middle East or Turkish ethnic ori-
gin (n = 915), none of the analyses revealed a significant 
relation between  N363S and blood pressure (all p > 0.2). 
Similarly, selective analyses of pure  N363S carriers 
against pure noncarriers (403 vs. 3,407 infants) did not 
confirm the effects observed in the entire cohort (all
p > 0.2).
 Regarding mechanical ventilation, logistic regression 
analysis with adjustment for gestational age only revealed 
a trend for the impact of  N363S (p = 0.060). Again, exclu-
sion of compound-heterozygous and double mutant in-
dividuals abolished the effects seen in the entire cohort 
(47.0 vs. 48.3%, p > 0.2).
 R23K 
 The  R23K variant did not influence any of the neonatal 
outcome parameters, neither in the entire cohort nor in 
subgroup analyses comparing only pure carriers against 
pure noncarriers (all p > 0.1).
 The infants included in our study were born over a 
considerably long period (2003–2013) during which as-
sistance of premature infants was developed further. In 
order to identify potential confounders related to chang-
es of neonatal care during this period, we compared the 
core parameters gestational age, BPD, and death accord-
ing to each birth year, but did not find significant differ-
ences in our cohort (online suppl. table S1; see www.
karger.com/doi/10.1159/000446908).
 Discussion 
 In the present study we have assessed the impact of 
polymorphisms in the  GR gene on neonatal outcome pa-
rameters in a cohort of 10,490 VLBW infants, which is the 
largest pediatric study on this topic so far. Although some 
previous studies found significant relations between  GR 
gene polymorphisms and several aspects of neonatal out-
come in preterm infants such as RDS, BPD  [9, 10] , and 
birth weight  [7] , the only significant association observed 
in our cohort was a slightly increased risk of developing 
BPD (OR 1.12–1.16 per allele) in carriers of the  BclI vari-
ant. Further associations observed in the group compari-
sons for  BclI (PVL, ROP, late-onset sepsis) and  N363S 
(RDS/mechanical ventilation, blood pressure) did not 
withstand adjustment for cross-genotype effects (e.g. me-
chanical ventilation and  N363S vs. BPD and  BclI ).
 Global and conditional gene-targeted respiratory 
mouse models of either glucocorticoid deficiency or glu-
cocorticoid receptor ablation have highlighted the crucial 
role of glucocorticoids and the glucocorticoid receptor 
for fetal lung development in utero  [17] . Therefore, func-
tional relevant polymorphisms in the  GR gene might 
modify lung maturation and/or neonatal respiratory out-
come parameters in preterm infants who are at risk for 
RDS. In a cohort of 62 preterm infants, Oretti et al. [8] did 
not detect associations between RDS and any of the three 
 GR gene polymorphisms. More recently, RDS risk was 
found to be associated with the maternal  GR genotype by 
Haas et al.  [9] , who analyzed the neonatal outcome of 117 
infants delivered by 109 mothers.  The authors observed a 
significantly lower RDS rate in infants of mothers carry-
ing the  BclI variant than in those born to wild-type moth-
ers. Further analysis of this cohort suggested an associa-
tion of  BclI with BPD (OR 2.56, 95% CI: 1.11–5.95, p = 
0.02), although multivariable analysis did not confirm 
this association in a subsequent publication of this group 
 [10] .  The cohort appeared too small to exclude potential 
confounding effects of compound heterozygosity or dou-
ble mutants. Furthermore, it was not possible to estimate 
the effect of antenatal steroid administration because all 
mothers had received prenatal betamethasone treatment 
in this study cohort.
 In our study, analysis of the whole cohort revealed 
slightly higher rates of mechanical ventilation in  N363S 
carriers and BPD in infants carrying the  BclI variant, re-
spectively. The effect on BPD remained statistically sig-
nificant after adjustment for gestational age, mechanical 
ventilation, and SGA status. It was of similar effect size in 
the subgroup of infants who received antenatal steroid 
treatment (n = 9,011, OR 1.15), whereas no significant 
genotype effect was seen in the subgroup of infants with-
out antenatal steroid treatment (n = 1,982, OR 0.96, n.s.). 
Of note, infants who received antenatal steroid treatment 
had a slightly higher BPD rate compared to those without 
prenatally given steroids (15.9 vs. 14.8%). These two 
groups, however, are not comparable in terms that those 
infants without prenatal steroids were more likely to be 
born either spontaneously (17.9 vs. 8.9%, p < 0.001) or by 
emergency Caesarean section (20.2 vs. 6.2%, p < 0.001), 
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and had higher birth weight (1,113 vs. 1,054 g, p < 0.001) 
as well as gestational age (28.87 vs. 28.23 weeks, p < 0.001). 
We further corrected for potential confounding effects of 
compound heterozygosity or double mutant individuals 
(e.g. rate of mechanical ventilation in  N363S carriers vs. 
BPD risk in  BclI carriers) and recalculated all analyses 
with only those infants being either  BclI pure carriers (i.e. 
wild-type at positions p.23 and p.363) or pure noncarriers 
(wild-type at all three polymorphic positions). This step, 
however, did not further strengthen the association be-
tween  BclI and BPD.
 Considering the increased receptor sensitivity of the 
 BclI variant, as reported from previous association studies 
 [18] , one may speculate a priori that the BPD rate should 
be lower in carriers of the  BclI variant and not vice versa 
as observed in our cohort. However, our results do not 
allow any speculation of whether differences in the BPD 
rate may result from differing levels of circulating endog-
enous glucocorticoid levels during pregnancy or after 
birth, or are indicative of a modified glucocorticoid re-
ceptor response to exogenous steroids. The fact that we 
did not see any relation of the  BclI genotype to preceding 
mechanical ventilation in our study sample and, further-
more, no clear genotype-related differences in circulating 
glucocorticoid levels can be detected at least in term neo-
nates during newborn screening  [11] favors the assump-
tion of a tissue-specific effect linked to a modification in 
the  GR action. Of note, although a greater response in a 
dexamethasone suppression test is generally indicative of 
 GR hypersensitivity, converse tissue-specific effects re-
garding the  GR response to synthetic corticoids have been 
discussed previously  [4, 19] .
 We are aware that we have analyzed only three select-
ed  GR gene polymorphisms. However, considering the 
heterogenous conclusions drawn from mostly small as-
sociation studies published on this topic so far, we fa-
vored analyzing a few  GR variants in a large multicenter 
cohort.  N363S and  R23K were selected because of their 
relevant functional effects shown in in vitro studies  [20, 
21] .  For the more frequent  BclI  variant, which has been 
linked to increased  GR sensitivity in several association 
studies, no in vitro transfection studies are available be-
cause this variant is not located within the coding region 
of the  GR gene. Due to the vicinity to a known splicing 
site, linkage to other functional polymorphisms has been 
speculated. Indeed, in the study of Rautanen et al. [22] 
who investigated the relationship of six  GR haplotypes to 
basal cortisol secretion, the  BclI variant was part of two 
haplotypes, but only one of these was associated with 
higher basal cortisol levels. Interestingly, a recent case-
control study on 675 preterm infants born with a gesta-
tional age less than 31 weeks did not find any association 
of 23 SNPs in the  GR gene with BPD  [23] ;  BclI ,  N363S, 
and  R23K , however, were not analyzed in this study.
 Given the almost ubiquitous  GR expression and the 
broad spectrum of clinical challenges in neonatal medi-
cine, other organ systems might also be affected by ge-
netic variation of the  GR gene. Both endogenous and ex-
ogenous glucocorticoids are well known to raise blood 
pressure. In our cohort, we detected an association be-
tween  N363S and blood pressure; however, it disappeared 
in the pure carrier analysis after excluding any compound 
heterozygotes and carriers of  BclI and  R23K . This is in line 
with findings of other pediatric and adult studies, which 
did not detect an association of  N363S and blood pressure 
later in life  [6, 24, 25] .
 Referring to the concept of early developmental ori-
gins of adult disease as initially proposed by Barker et al. 
 [26] , low birth weight itself has been associated with the 
predisposition to metabolic-related disorders in numer-
ous clinical studies  [27] .
 In line with findings from a study comprising more 
than 2,400 term and late preterm infants  [28] , we did not 
detect any association between  GR polymorphisms and 
either birth weight or being born SGA in our cohort. In-
terestingly, Finken et al.  [5] reported carriers of the  GR 
 R23K variant to be protected from postnatal growth fail-
ure after preterm birth. Considering the assumed close 
relationship between the individual pattern of postnatal 
catch-up growth and metabolic sequelae of low birth 
weight, this finding certainly warrants further investiga-
tion.
 Our study has some limitations. First, the study par-
ticipants were enrolled over a relatively long period of 
time, namely 10 years, and assistance to premature in-
fants, survival, and outcome of VLBW infants has changed 
considerably in the last two decades. Although there were 
no significant differences with respect to the core param-
eters gestational age, BPD, and death in our cohort, other 
variables may have been affected by medical and technical 
progress and could thus have masked further associations 
between  GR variants and neonatal outcome parameters. 
Second, some of the analyzed neonatal outcome param-
eters are susceptive to inaccuracy arising from center-
specific treatment algorithms in our cohort which com-
prises infants from a large number of neonatal units (e.g. 
initial ventilation support, indication and timing of sur-
gery for ROP, PDA, and NEC). Third, the statistical pow-
er of our large sample of over 10,000 neonates is still de-
batable, especially in view of a variety of tested neonatal 
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outcome parameters with low prevalence in the total 
VLBW cohort and comparatively low genotype frequen-
cies for polymorphisms  N363S and  R23K . Even for the 
observed association between BPD and the frequent  BclI 
variant (1,584 BPD cases, OR 0.12–0.15), a power calcula-
tion yielded BPD case numbers between 1,423 and 1,805 
(dominant 1 df/allelic 1 df test) necessary to reach 80% 
power (p = 0.05).
 In summary, except for a slightly higher risk of BPD 
(OR 1.12–1.16 per allele) in carriers of the  GR  BclI variant, 
 GR gene polymorphisms  BclI ,  N363S , and  R23K did not 
affect early neonatal outcome parameters in our large 
multicenter cohort of >10,000 VLBW preterm infants. In 
the near future, increasingly available genome-wide as-
sociation studies together with large-scaled multicenter 
approaches will help to clarify whether and to what extent 
single genomic variants (alone or enriched in polygenetic 
clusters connecting biological pathways  [29] ) can predict 
individual risks during the challenging clinical course af-
ter preterm birth.
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